Iveric to seek FDA approval for drug ahead of schedule; shares up

IVERIC bio

03/11/2022 15:00

** Shares of eye-disease drug maker Iveric bio Inc  ISEE.O  
up 2.8% at $23.47
    ** Co says it is ahead of schedule to seek regulatory
approval from the U.S. FDA for Zimura
    ** The drug is a potential treatment for geographic atrophy,
an age-related disorder which leads to visual function loss
    ** ISEE says moving the timeline for submission of its
marketing application to end of 2022 from previously expected
end of Q1 2023 
    ** Co says it has also received favorable feedback from the
FDA on its development plans for the treatment of age-related
macular degeneration  
    ** ISEE also reports Q3 loss of $42.4 million, or 35 cents
per share
    ** Including session's gains, stock had risen ~37% YTD
compared with a ~14% decline in the Nasdaq Biotechnology index
 .NBI 
 (Reporting by Sriparna Roy)
 ((Sriparna.roy@thomsonreuters.com))